|
業務類別
|
-- |
|
業務概覽
|
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its globalfootprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025. |
| 公司地址
| 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426 |
| 電話號碼
| +81 362251111 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.daiichisankyo.co.jp |
| 員工數量
| 19765 |
| Mr. Hiroyuki Okuzawa |
Director, President and Chief Executive Officer |
-- |
19/06/2026 |
| Mr. Takashi Matsumoto |
Director and Senior Executive Officer |
-- |
19/06/2026 |
|
|
| Mr. Joseph Kenneth Keller |
Director |
19/06/2026 |
| Mr. Takaaki Nishii |
Independent Director |
19/06/2026 |
| Mr. Hiroyuki Okuzawa |
Director, President and Chief Executive Officer |
19/06/2026 |
| Mr. Yo Honma |
Independent Director |
19/06/2026 |
| Mr. Yasuhiro Komatsu |
Independent Director |
19/06/2026 |
| Mr. Takashi Matsumoto |
Director and Senior Executive Officer |
19/06/2026 |
| Ms. Reiko Kinoshita |
Independent Director |
19/06/2026 |
| Ms. Shizuko Ueno |
Director |
19/06/2026 |
| Mr. Akihiro Watanabe |
Independent Director |
19/06/2026 |
| Mr. Stuart Mackey |
Director |
19/06/2026 |
|
|
|
|
